121 related articles for article (PubMed ID: 30793359)
1. Synthesis of di-docosahexaenoyl (C22:6)-bis(monoacylglycerol) phosphate in unlabelled and C-13 labelled forms for use as a biomarker of drug induced phospholipidosis.
Hickey MJ; Lindqvist J; Ha YH; Andersson H; Elmore CS
J Labelled Comp Radiopharm; 2019 Sep; 62(11):695-706. PubMed ID: 30793359
[TBL] [Abstract][Full Text] [Related]
2. Di-22:6-bis(monoacylglycerol)phosphate: A clinical biomarker of drug-induced phospholipidosis for drug development and safety assessment.
Liu N; Tengstrand EA; Chourb L; Hsieh FY
Toxicol Appl Pharmacol; 2014 Sep; 279(3):467-476. PubMed ID: 24967688
[TBL] [Abstract][Full Text] [Related]
3. Qualified method for the estimation of di-18:1 bis(monoacylglycero)phosphate in urine, a noninvasive biomarker to monitor drug-induced phospholipidosis.
Murali BV; Kurawattimath V; Bhutani P; Onorato J; Naikodi SB; Kole P; Rajanna PK
Bioanalysis; 2020 Aug; 12(15):1049-1059. PubMed ID: 32735140
[No Abstract] [Full Text] [Related]
4. Bis(monoacylglycero)phosphate, a peculiar phospholipid to control the fate of cholesterol: Implications in pathology.
Hullin-Matsuda F; Luquain-Costaz C; Bouvier J; Delton-Vandenbroucke I
Prostaglandins Leukot Essent Fatty Acids; 2009; 81(5-6):313-24. PubMed ID: 19857945
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the diagnostic accuracy of di-22:6-bis(monoacylglycerol)phosphate and other urinary phospholipids for drug-induced phospholipidosis or tissue injury in the rat.
Thompson KL; Haskins K; Rosenzweig BA; Stewart S; Zhang J; Peters D; Knapton A; Rouse R; Mans D; Colatsky T
Int J Toxicol; 2012; 31(1):14-24. PubMed ID: 22267869
[TBL] [Abstract][Full Text] [Related]
6. Phospholipidosis in rats treated with amiodarone: serum biochemistry and whole genome micro-array analysis supporting the lipid traffic jam hypothesis and the subsequent rise of the biomarker BMP.
Mesens N; Desmidt M; Verheyen GR; Starckx S; Damsch S; De Vries R; Verhemeldonck M; Van Gompel J; Lampo A; Lammens L
Toxicol Pathol; 2012 Apr; 40(3):491-503. PubMed ID: 22291062
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers to monitor drug-induced phospholipidosis.
Baronas ET; Lee JW; Alden C; Hsieh FY
Toxicol Appl Pharmacol; 2007 Jan; 218(1):72-8. PubMed ID: 17156806
[TBL] [Abstract][Full Text] [Related]
8. Comparison of urinary and serum levels of di-22:6-bis(monoacylglycerol)phosphate as noninvasive biomarkers of phospholipidosis in rats.
Thompson KL; Zhang J; Stewart S; Rosenzweig BA; Shea K; Mans D; Colatsky T
Toxicol Lett; 2012 Sep; 213(2):285-91. PubMed ID: 22828012
[TBL] [Abstract][Full Text] [Related]
9. The Emerging and Diverse Roles of Bis(monoacylglycero) Phosphate Lipids in Cellular Physiology and Disease.
Showalter MR; Berg AL; Nagourney A; Heil H; Carraway KL; Fiehn O
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33137979
[TBL] [Abstract][Full Text] [Related]
10. An efficient Perkin synthesis of
Lenz D; Koeppe B; Tolstoy PM; Limbach HH
J Labelled Comp Radiopharm; 2019 Jun; 62(7):298-300. PubMed ID: 31125993
[TBL] [Abstract][Full Text] [Related]
11. The role of lysosomal phospholipase A2 in the catabolism of bis(monoacylglycerol)phosphate and association with phospholipidosis.
Abe A; Hinkovska-Galcheva V; Bouchev P; Bouley R; Shayman JA
J Lipid Res; 2024 Jun; 65(7):100574. PubMed ID: 38857781
[TBL] [Abstract][Full Text] [Related]
12. Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities.
Tengstrand EA; Miwa GT; Hsieh FY
Expert Opin Drug Metab Toxicol; 2010 May; 6(5):555-70. PubMed ID: 20370598
[TBL] [Abstract][Full Text] [Related]
13. Imaging Mass Microscopy of Kidneys from Azithromycin-Treated Rats with Phospholipidosis.
Sakurai T; Kamio K; Sasaki K; Nishimoto T; Yamaguchi JI; Sasaki M; Tsutsumi S
Am J Pathol; 2018 Sep; 188(9):1993-2003. PubMed ID: 29981744
[TBL] [Abstract][Full Text] [Related]
14. Identification of drugs inducing phospholipidosis by novel in vitro data.
Muehlbacher M; Tripal P; Roas F; Kornhuber J
ChemMedChem; 2012 Nov; 7(11):1925-34. PubMed ID: 22945602
[TBL] [Abstract][Full Text] [Related]
15. In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Fischer H; Atzpodien EA; Csato M; Doessegger L; Lenz B; Schmitt G; Singer T
J Med Chem; 2012 Jan; 55(1):126-39. PubMed ID: 22122484
[TBL] [Abstract][Full Text] [Related]
16. A multiplexed UPLC-MS/MS assay for the simultaneous measurement of urinary safety biomarkers of drug-induced kidney injury and phospholipidosis.
Tengstrand E; Zhang H; Liu N; Dunn K; Hsieh F
Toxicol Appl Pharmacol; 2019 Mar; 366():54-63. PubMed ID: 30653977
[TBL] [Abstract][Full Text] [Related]
17. Role of bis(monoacylglycero)phosphate in propranolol binding to phospholipid membranes under acidic conditions as measured by high-performance frontal analysis/capillary electrophoresis.
Hamaguchi R; Kuroda Y; Tanimoto T; Haginaka J
Electrophoresis; 2012 Oct; 33(19-20):3101-6. PubMed ID: 22996699
[TBL] [Abstract][Full Text] [Related]
18. Excessive dietary lipid intake provokes an acquired form of lysosomal lipid storage disease in the kidney.
Rampanelli E; Ochodnicky P; Vissers JP; Butter LM; Claessen N; Calcagni A; Kors L; Gethings LA; Bakker SJ; de Borst MH; Navis GJ; Liebisch G; Speijer D; van den Bergh Weerman MA; Jung B; Aten J; Steenbergen E; Schmitz G; Ballabio A; Florquin S; Aerts JM; Leemans JC
J Pathol; 2018 Dec; 246(4):470-484. PubMed ID: 30073645
[TBL] [Abstract][Full Text] [Related]
19. Practical enantiospecific syntheses of lysobisphosphatidic acid and its analogues.
Jiang G; Xu Y; Prestwich GD
J Org Chem; 2006 Feb; 71(3):934-9. PubMed ID: 16438504
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of stable isotope-labelled firocoxib.
Latli B; Gao A; Kvaternick V; Tecle B; Pennino S; Yee NK; Song J
J Labelled Comp Radiopharm; 2020 Jun; 63(8):386-392. PubMed ID: 32307719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
